Curium’s $8B Lantheus Deal Makes Shareholders Sell the Upside
Curium is paying $102.50 a share for Lantheus now — then asking shareholders to wait until 2030 for the last $12. That is not generosity. It is a very clever way to buy growth without fully paying for it today.
Curium is paying $102.50 a share for Lantheus now — then asking shareholders to wait until 2030 for the last $12. That is not generosity. It is a very clever way to buy growth without fully paying for it today.
On August 3, Curium agreed to acquire Lantheus Holdings in a transaction worth up to $8 billion. It is one of those deals that sounds simple until you inspect where the money actually goes.
Lantheus shareholders get $102.50 per share in cash at closing. They can receive another $12 per share through contingent value rights, or CVRs, if Lantheus products hit a series of sales targets by 2030. The maximum headline price is $114.50 per share. The guaranteed price is $102.50.
That gap is the whole story.
The $8 billion headline is not the cheque
Let’s call it plainly: Curium is not writing an $8 billion cheque on day one.
The upfront cash consideration implies roughly $6.7 billion of value for Lantheus. The remaining potential value sits inside performance milestones that may or may not be met. Curium and Lantheus have structured the deal so the seller gets certainty now, while the buyer keeps a meaningful slice of the future upside for itself if the business underperforms.
That is good dealmaking.
The $102.50 cash payment represented a 21% premium to Lantheus’ unaffected closing price on May 21, 2026 — the last trading day before the first media report of a potential transaction. Measured against unaffected 60-day volume-weighted average pricing, the company says the maximum consideration represents a 38% premium.
Investors should not confuse a premium with a bargain. A premium merely means the buyer paid more than yesterday’s share price. If yesterday’s price failed to capture the commercial potential of prostate diagnostics, neurology imaging and cardiac imaging, then the seller can still be leaving plenty on the table.
And Lantheus has enough commercial firepower that this is not some science-project acquisition. Its portfolio includes PYLARIFY in prostate cancer imaging, Neuraceq in neurology diagnostics and DEFINITY in cardiac imaging. Curium brings a global radiopharmaceutical manufacturing footprint, a theranostics pipeline and operations in more than 70 countries.
This is a serious industrial combination, not a banker’s PowerPoint marriage.
Curium is buying the full nuclear-medicine machine
Radiopharmaceuticals are becoming one of the more valuable corners of healthcare because they sit where diagnosis, manufacturing and treatment collide.
A traditional drug company can manufacture pills or biologics in huge batches, ship them broadly and worry about the rest later. Nuclear medicine is less forgiving. Isotopes decay. Production capacity matters. Distribution timing matters. Hospital relationships matter. Regulatory approvals matter. If any link in the chain is weak, the product might as well not exist.
That is why Curium’s purchase of Lantheus makes strategic sense.
Curium is effectively buying more than a product catalogue. It is buying a U.S. commercial platform, established diagnostic franchises and a deeper place in the patient journey. Lantheus helps clinicians find disease. Curium wants to pair that diagnostic presence with its radioligand-therapy ambitions — the part designed to fight disease.
The combined company is intended to span isotope production, manufacturing, diagnostic imaging and targeted radionuclide therapy. In business terms, Curium is moving from being a supplier inside the value chain to owning more of the value chain.
That is where the money is.
Anyone who has built a business knows the difference. Selling one useful component is fine. Owning the customer relationship, the route to market, the operational bottleneck and the next product is better. It gives you more control, more pricing power and more ways to win when the market grows.
Curium was established by CapVest in 2017, and CapVest remains its controlling shareholder. In 2025, Curium was recapitalised in a transaction that valued the group at about $7 billion. Now it is attempting an acquisition with a maximum value of $8 billion. That tells you how aggressively private equity sees the opportunity in nuclear medicine.
Not next year. Now.
The CVR is where the buyer shows its hand
The extra $12 per Lantheus share is tied to specific commercial outcomes. That matters because vague earn-outs are where optimism goes to die. These targets are at least concrete.
Shareholders can earn up to $8 per share from global prostate-cancer diagnostics sales milestones in the 2030 financial year. Payments start when sales exceed $950 million and rise through thresholds above $1.1 billion, $1.2 billion, $1.5 billion and $1.75 billion.
Another $3 per share is tied to global neurology-diagnostics sales reaching more than $300 million and then $350 million in any one of 2028, 2029 or 2030. The final $1 per share depends on the global DEFINITY business exceeding $400 million in 2030.
Now, the bit most people skip: these CVRs are non-transferable.
That means shareholders cannot simply sell the right separately if they decide they want cash today rather than wait around until 2030. They own the claim, but they do not own liquidity. That makes the CVR less valuable than a clean cash payment of the same nominal amount.
A dollar in four years is not a dollar today. A conditional dollar in four years is even less so.
The market understands this. That is why the sensible way to assess the deal is not to say, “Curium paid $114.50 per share.” The sensible assessment is: Curium paid $102.50 in real money, plus a performance-linked instrument that could pay up to $12 if several commercial targets are achieved.
I do not say that to be cynical. I say it because founders and investors get burned when they let headline value replace economic value.
The overlooked angle: Curium may have got the better side of the risk
Most coverage of large M&A deals focuses on whether the target received a premium. Fair enough. But the sharper question is: who carries the downside after closing?
Here, Curium has put a meaningful part of the purchase price against revenue targets tied to assets it will control after the deal closes.
That is the clever bit.
Once Lantheus becomes private, Curium will control capital allocation, commercial priorities, manufacturing investment and the integration agenda. If the milestones are missed, shareholders miss the CVR payments. Curium still owns the business and retains any long-term value created beyond the contract terms.
To be clear, this is not evidence of bad faith. It is simply the reality of incentive design. A buyer that can acquire a company with substantial cash upfront and shift part of the growth risk back to departing shareholders has negotiated well.
Lantheus’ board says it considered multiple strategic options, including remaining standalone, and unanimously concluded that the Curium transaction was the value-maximising path. There may well have been no better fully financed offer on the table. Boards do not get to approve imaginary bids.
But founders should learn the lesson anyway: if your business has obvious upside, a buyer will try to label part of it “contingent.” Your job is to decide whether that contingency is genuinely shared risk or merely deferred payment for value you have already built.
Those are not the same thing.
Why the deal is bigger than one healthcare transaction
This acquisition is another reminder that the best M&A targets are not always sexy consumer brands or AI companies with inflated valuations. Often they are businesses sitting on an operational choke point.
Radiopharmaceuticals require specialised manufacturing, logistics, regulatory competence, technical talent and clinical distribution. That combination is hard to replicate. And when demand rises, capacity and execution become more valuable than a nice-looking slide deck.
Curium is betting that owning more of this system will matter more than simply owning another therapy candidate.
That logic applies well beyond healthcare. In any industry, ask where the bottleneck sits. Is it distribution? Compliance? Manufacturing capacity? Customer trust? Proprietary data? A hard-won sales channel?
The business that owns the bottleneck usually earns more than the business that merely participates in the trend.
What this means for you
If you are an investor, stop valuing acquisition offers by their biggest number. Split every deal into three buckets: cash at close, genuinely liquid securities, and contingent consideration. Then discount the contingent bit hard. If the upside depends on milestones years away and you cannot sell the right separately, it is not worth face value.
If you are a founder, build assets buyers cannot cheaply recreate. A great product is helpful. A product plus regulatory know-how, specialist infrastructure, distribution and customer trust is what gets strategic buyers interested.
And if you are an operator, pay attention to the CVR lesson. The best negotiations are not won by arguing about price alone. They are won by deciding who carries risk, who controls the levers after the deal, and whether the payment terms match that reality.
Curium has made a bold bet on nuclear medicine. But it has not made a reckless one. It has paid Lantheus shareholders real money today, while making them keep some skin in the commercial targets of tomorrow.
That is not romance. That is M&A done properly.